Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: Theory versus promise

Clinical Science

Volumn 113, Issue 3-4, 2007, Pages 183-193

  Li, Xiao ^a   Zhuo, Jia L ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic nephropathy; Glucagon; Hyperglycaemia; Insulin; Metabolic syndrome; Type 2 diabetes

Indexed keywords

1 N ALPHA TRINITROPHENYLHISTIDINE,12 HOMOARGININE GLUCAGON; 2 (BENZIMIDAZOL 2 YLTHIO) 1 (3,4 DIHYDROXYPHENYL) 1 ETHAN ONE; 2 (BENZIMIDAZOL 2 YLTHIO) 1 (3,4 DIHYDROXYPHENYL) 1 ETHANONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BAY 27 9955; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; EXENDIN 4; GLUCAGON; GLUCAGON RECEPTOR; INSULIN; LIRAGLUTIDE; SITAGLIPTIN; TELMISARTAN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERGLUCAGONEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY INJURY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 34547807704     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070040     Document Type: Review

References (89)

1. Mayo, K. E., Miller, L. J., Bataille, D. et al. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167-194
2. Jiang, G. and Zhang, B. B. (2003) Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284, E671-E678
3. Gromada, J., Franklin, I. and Wollheim, C. B. (2007) α cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28, 84-116
4. Matthaei, S., Stumvoll, M., Kellerer, M. and Haring, H-U. (2000) Pathophysiology and Pharmacological treatment of insulin resistance. Endocr. Rev. 21, 585-618
5. Bromer, W. W., Sinn, L. G., Staub, A. and Behrens, O. K. (1956) The amino acid sequence of glucagon. J. Am. Chem. Soc. 78, 3858-3859
6. Baum, J., Simon, B. F., Unger, R. H. and Madison, L. L. (1962) Localization of glucagon in the α cells in the pancreatic islet by immunofluorescent techniques. Diabetes 11, 371-374
7. Lund, P. K., Goodman, R. H., Dee, P. C. and Habener, J. F. (1982) Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc. Natl. Acad. Sci. U.S.A. 79, 345-349
8. Jelinek, L. J., Lok, S., Rosenberg, G. B. et al. (1993) Expression cloning and signaling properties of the rat glucagon receptor. Science 259, 1614-1616
9. Lok, S., Kuijper, J. L., Jelinek, L. J. et al. (1994) The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene 140, 203-209
10. Furuta, M., Zhou, A., Webb, G. et al. (2001 ) Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J. Biol. Chem. 20, 27197-27202
11. Rouille, Y., Westermark, G., Martin, S. K. and Steiner, D. F. (1994) Proglucagon is processed to glucagon by prohormone convertase PC2 in αTC1-TC6 cells. Proc. Natl. Acad. Sci. U.S.A. 91, 3242-3246
12. Webb, G. C., Akbar, M. S., Zhao, C., Swift, H. H. and Steiner, D. F. (2002) Glucagon replacement via micro-osmotic minipump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51, 398-405
13. 125I]glucagon binding in rat tubules. Pflugers Arch. 404, 348-353
14. Marks, J., Debnam, E. S., Dashwood, M. R., Srai, S. K. and Unwin, R. J. (2003) Detection of glucagon receptor mRNA in the rat proximal tubule: potential role for glucagon in the control of renal glucose transport. Clin. Sci. 104, 253-258
15. 9]glucagon amide, a glucagon antagonist. Peptides 10, 1171-1177
16. Buggy, J. J., Heurich, R. O., MacDougall, M. et al. (1997) Role of the glucagon receptor COOH-terminal domain in glucagon-mediated signaling and receptor internalization. Diabetes 46, 1400-1405
17. Petersen, K. F. and Sullivan, J. T. (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44, 2018-2024
18. Gelling, R. W., Du, X. Q., Dichmann, D. S. et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100, 1438-1443
19. Vuguin, P. M., Kedees, M. H., Cui, L. et al. (2006) Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 147, 3995-4006
20. Parker, J. C., Andrews, K. M., Allen, M. R., Stock, J. L. and McNeish, J. D. (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290, 839-843
21. Rodbell, M., Birnbaumer, L., Pohl, S. L. and Krans, H. M. (1971) The glucagon-sensitive adenylyl cyclase system in plasma membranes of rat liver. V. an obligatory role of guanylnucleotides in glucagon action. J. Biol. Chem. 246, 1877-1882
22. Wakelam, M. J., Murphy, G. J., Hruby, V. J. and Houslay, M. D. (1986) Activation of two signal-transduction systems in hepatocytes by glucagon. Nature 323, 68-71
23. Seino, S. and Shibasaki, T. (2005) PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol. Rev. 85, 1303-1342
24. 2+ signaling in BHK cells expressing cloned human glucagon receptors. Am. J. Physiol. 274, C1552-C1562
25. Reaven, G. M., Chen, Y. D., Golay, A., Swislocki, A. L. and Jaspan, J. B. (1987) Documentation of hyperglucagonemia through the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 64, 106-110
26. Orskov, C., Jeppesen, J., Madsbad, S. and Hoist, J. J. (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87, 415-423
27. Barazzoni, R., Zanetti, M., Davanzo, G. et al. (2000) Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J. Clin. Endocrinol. Metab. 85, 3121-3125
28. Unger, R. H. (1978) Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metab. Clin. Exp. 27, 1691-1709
29. Unger, R. H. (1985) Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28, 574-578
30. Shah, P., Vella, A., Basu, A, Basu, R, Schwenk, W. F. and Rizza, R. A. (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85, 4053-4059
31. Salehi, A., Vieira, E. and Gylfe, E. (2006) Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 55, 2318-2323
32. Harris, P. J., Skinner, S. L. and Zhuo, J. L. (1988) The effects of atrial natriuretic peptide and glucagon on proximal glomerulotubular balance in anesthetized rats. J. Physiol. 402, 29-42
33. Premen, A. J., Hall, J. E. and Smith, L. J. (1985) Postprandial regulation of renal hemodynamics: role of pancreatic glucagon. Am. J. Physiol. 248, F656-F662
34. Tolins, J. P. (2004) Mechanisms of glucagon-induced renal vasodilation: role of prostaglandins and endothelium-derived relaxing factor. J. Lab. Clin. Med. 120, 941-948
35. Ahloulay, M., Decaux, M., Laborde, K. and Bankir, L. (1995) Influence of glucagon on GFR and on urea and electrolyte excretion: direct and indirect effects. Am. J. Physiol. 38, F225-F235
36. Ahloulay, M. and Bankir, L. (1996) Glucagon antibody infusion reduces GFR in diabetic rats. J. Am. Soc. Nephrol. 7, 1868a
37. Sorensen, H., Brand, C. L., Neschen, S. et al. (2006) Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55, 2843-2848
38. Ahloulay, M., Dechaux, M., Hassler, C., Bouby, N. and Bankir, L. (1996) Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J. Clin. Invest. 98, 2251-2258
39. Nikolaidis, L. A., Elahi, D., Hentosz, T. et al. (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955-961
40. Gartner, K. (1978) Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db). Diabetologia 15, 59-63
41. Levine, D. Z., Iacovitti, M., Robertson, S. J. and Mokhtar, G. A. (2006) Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R975-R981
42. Breyer, M. D., Bottinger, E., Brosius, III, F. C. et al. (2005) Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 27-45
43. Amiri, F, Venema, V. J., Wang, X., Ju, H., Venema, R. C. and Marrero, M. B. (1999) Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J. Biol. Chem. 274, 32382-32386
44. Park, S. H., Woo, C. H., Kim, J. H. et al. (2002) High glucose down-regulates angiotensin II binding via the PKC-MAPK-cPLA2 signal cascade in renal proximal tubule cells. Kidney Int. 61, 913-925
45. Singh, R., Alavi, N. Singh A. K. and Leehey, D. J. (1999) Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48, 2066-2073
46. Jiang, Y., Cypess, A. M., Muse, E. D. et al. (2001) Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 98, 10102-10107
47. Dalle, S., Longuet, C., Costes, S. et al. (2004) Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK 1/2 in MIN6 cell line and isolated islets of Langerhans. J. Biol. Chem. 279, 20345-20355
48. Li, X. C., Carretero, O. A., Shao, Y. and Zhuo, J. L. (2006) Glucagon receptor-mediated ERK 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C. Hypertension 47, 580-585
49. Li, X. C., Carretero, O. A. and Zhuo, J. L. (2006) Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells. Biochem. Pharmacol. 71, 1711-1719
50. 2+ influx through L-type voltage-gated calcium channels mediated raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β cells. J. Biol. Chem. 277, 48146-48151
51. Kemp, D. M. and Habener, J. F. (2001) Insulinotrophic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology 142, 1179-1187
52. Brenner, B. M., Cooper, M. E., de Zeeuw, D. et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869
53. Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B and Lishner, M. (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann. Intern. Med. 118, 577-581
54. Lewis, E. J., Hunsicker, L. G., Bain, R. P. and Rohde, R. D. (1993) The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462
55. Hostetter, T. H. (2003) Hyperfiltration and glomerulosclerosis. Semin. Nephrol. 23, 194-199
56. Sochett, E. B., Cherney, D. Z., Curtis, J. R., Dekker, M. G., Schpley, J. W. and Miller, J. A. (2006) Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J. Am. Soc. Nephrol. 17, 1703-1709
57. Barnett, A. H., Bain, S. C., Bouter, P. et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 351, 1952-1961
58. Zhuo, J. L., Harris, P. J. and Skinner, S. L. (2003) ACE inhibition prevents glucagon-induced glomerular hyperfiltration in anesthetized rats. FASEB J. 17, A923
59. Li, X. C., Shao, Y., D'Ambrosio, M. and Zhuo, J. L. (2006) Long-term hyperglucagonemia induces metabolic and renal phenotypes of early type 2 diabetes in mice: effects of glucagon receptors and angiotensin II. Hypertension. 48, e75
60. Wilkes, B. M., Mento, P. F. and Vernace, M. A. (1993) Angiotensin responsiveness in hyperfiltering and nonhyperfiltering diabetic rats. J. Am. Soc. Nephrol. 4, 1346-1353
61. Singh, R., Singh, A. K. and Leehey, D. J. (2005) A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am. J. Physiol. Renal Physiol. 288, F1183-F1190
62. Carey, R. M. and Siragy, H. M. (2003) The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 14, 274-281
63. Singh, R., Singh, A. K., Alavi, N. and Leehey, D. J. (2003) Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J. Am. Soc. Nephrol. 14, 873-880
64. Vidotti, D. B., Casarini, D. E., Cristovam, P. C., Leite, C. A., Schor, N. and Boim, M. A. (2004) High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am. J. Physiol. Renal Physiol. 286, F1039-F1045
65. Riser, B. L., Denichilo, M., Cortes, P. et al. (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11, 25-38
66. Isono, M., Cruz, M. C., Chen, S., Hong, S. W. and Ziyadeh, F. N. (2000) Extracellular signal-regulated kinase mediates stimulation of TGF-β1 and matrix by high glucose in mesangial cells. J. Am. Soc. Nephrol. 11, 2222-2230
67. Banes, A. K., Shaw, S., Jenkins, J. et al. (2004) Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am. J. Physiol. Renal Physiol. 286, F653-F659
68. Johnson, D. G., Goebel, C. U., Hruby, V. J., Bregman, M. D. and Trivedi, D. (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215, 1115-1116
69. Ling, A., Hong, Y., Gonzalez, J. et al. (2001) Identification of alkylidene hydrazides as glucagon receptor antagonists. J. Med. Chem. 44, 3141-3149
70. Madsen, P., Ling, A., Plewe, M. et al. (2002) Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6- tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J. Med. Chem. 45, 5755-5775
71. Qureshi, S. A., Rios, C. M., Xie, D. et al. (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53, 3267-3273
72. Madsen, P., Knudsen, L. B., Wiberg, F. C. and Carr, R. D. (1998) Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J. Med. Chem. 41, 5150-5157
73. Liang, Y., Osborne, M. C., Monia, B. P. et al. (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice, Diabetes 53, 410-417
74. Sloop, K. W., Cao, J. X., Siesky, A. M. et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J. Clin. Invest. 113, 1571-1581
75. Drucker, D. J. (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metab. 1, 22-31
76. Hoist, J. J. (2006) Glucagon-like peptide-1: from extract to agent. Diabetologia 49, 253-260
77. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44, 1126-1131
78. Hinke, S. A., Pospisilik, J. A., Demuth, H-U. et al. (2000) Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. J. Biol. Chem. 276, 3827-3834
79. Fehmann, H. C. and Habener, J. F. (1992) Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma β TC-1 cells. Endocrinology 130, 159-166
80. Gutniak, M., Orskov, C., Holst, J. J., Ahren, B. and Efendic, S. (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med.. 326, 1316-1322
81. Deacon, C. F. (2005) MK-431 (Merck). Curr. Opin. Invest. Drugs 6, 419-426
82. Herman, G. A., Bergman, A., Stevens, C. et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91, 4612-4619
83. Mari, A., Sallas, W. M., He, Y. L. et al. (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 90, 4888-4894
84. Ahren, B., Landin-Olsson, M., Jansson, P. A., Svensson, M., Holmes, D. and Schweizer, A. (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 2078-2084
85. Parkes, D. G., Pittner, R., Jodka, C., Smith, P. and Young, A. (2001) Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metab. Clin. Exp. 50, 583-589
86. Buse, J. B., Henry, R. R., Han, J. et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635
87. Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G. and Matthews, D. R. (2004) Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27, 1335-13342
88. Egan, J. M., Clocquet, A. R. and Elahi, D. (2002) The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 87, 1282-1290
89. Feinglos, M. N., Saad, M. E, Pi-Sunyer, F. X., An, B. and Santiago, O. (2005) Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycemic control and body weight in subjects with Type 2 diabetes. Diabetic Med. 22, 1016-1023